JP2022526842A5 - - Google Patents

Info

Publication number
JP2022526842A5
JP2022526842A5 JP2021559986A JP2021559986A JP2022526842A5 JP 2022526842 A5 JP2022526842 A5 JP 2022526842A5 JP 2021559986 A JP2021559986 A JP 2021559986A JP 2021559986 A JP2021559986 A JP 2021559986A JP 2022526842 A5 JP2022526842 A5 JP 2022526842A5
Authority
JP
Japan
Application number
JP2021559986A
Other languages
Japanese (ja)
Other versions
JP2022526842A (ja
JPWO2020210697A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027762 external-priority patent/WO2020210697A1/en
Publication of JP2022526842A publication Critical patent/JP2022526842A/ja
Publication of JP2022526842A5 publication Critical patent/JP2022526842A5/ja
Publication of JPWO2020210697A5 publication Critical patent/JPWO2020210697A5/ja
Pending legal-status Critical Current

Links

JP2021559986A 2019-04-12 2020-04-10 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法 Pending JP2022526842A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833228P 2019-04-12 2019-04-12
US62/833,228 2019-04-12
US202062988748P 2020-03-12 2020-03-12
US62/988,748 2020-03-12
PCT/US2020/027762 WO2020210697A1 (en) 2019-04-12 2020-04-10 Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Publications (3)

Publication Number Publication Date
JP2022526842A JP2022526842A (ja) 2022-05-26
JP2022526842A5 true JP2022526842A5 (https=) 2023-04-17
JPWO2020210697A5 JPWO2020210697A5 (https=) 2023-04-17

Family

ID=72748579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559986A Pending JP2022526842A (ja) 2019-04-12 2020-04-10 脂質ベースのナノ粒子および最適化されたインスリン投薬レジメンにおけるその使用方法

Country Status (7)

Country Link
US (3) US10918700B2 (https=)
EP (1) EP3952904A4 (https=)
JP (1) JP2022526842A (https=)
AU (1) AU2020271901A1 (https=)
CA (1) CA3136665A1 (https=)
WO (1) WO2020210697A1 (https=)
ZA (1) ZA202108217B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
WO2018169954A1 (en) * 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863896A (en) * 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
AU3999699A (en) * 1998-05-19 1999-12-06 Sdg, Inc. Targeted liposomal drug delivery system
CA2389236A1 (en) 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1448252B1 (de) * 2001-11-16 2007-04-18 Medinnovation AG Medizinische pumpvorrichtung
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US8211430B2 (en) * 2005-03-04 2012-07-03 Curedm Group Holdings, Llc Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
CN101237854B (zh) * 2005-05-23 2013-03-27 Sdg公司 将胰岛素输送到哺乳动物的脂构建体
US20110135725A1 (en) 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
WO2010080976A1 (en) * 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2018169954A1 (en) 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
EP3483629B1 (en) * 2017-11-09 2021-12-29 Veoneer Sweden AB Detecting a parking row with a vehicle radar system
KR20200106912A (ko) 2018-01-05 2020-09-15 에스디지,인코포레이티드 당뇨병을 치료하기 위한 지질 기반 나노입자를 포함하는 조성물

Similar Documents

Publication Publication Date Title
BR112023012656A2 (https=)
BR112023009656A2 (https=)
JP2022526842A5 (https=)
BR112023011738A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)
BR102021016200A2 (https=)
BR102021015450A8 (https=)
BR102021015247A2 (https=)
BR102021015220A2 (https=)
BR102021014056A2 (https=)
BR102021014044A2 (https=)
BR102021013929A2 (https=)